

PCT

**WORLD INTELLECTUAL PROPERTY ORGANIZATION**  
**International Bureau**



82



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 :  C07D 471/04, C07C 65/11, A61K 31/505 // (C07D 471/04, 239:00, 221:00)		A1	(11) International Publication Number: <b>WO 94/25460</b>
			(43) International Publication Date: 10 November 1994 (10.11.94)
(21) International Application Number:	PCT/EP94/01296		(81) Designated States: AU, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date:	22 April 1994 (22.04.94)		
(30) Priority Data:	93201216.4 28 April 1993 (28.04.93)	EP	
	(34) Countries for which the regional or international application was filed:	DE et al.	
(71) Applicant (for all designated States except US):	JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).		
(72) Inventors; and			
(75) Inventors/Applicants (for US only):	MESENS, Jean, Louis [BE/BE]; Moereind 17, B-2275 Wechelderzande (BE). PEETERS, Jozef [BE/BE]; Sint Corneliusstraat 64, B-2340 Beerse (BE).		
(74) Agent:	QUAGHEBEUR, Luc; Janssen Pharmaceutica N.V., Patent Dept., Turnhoutseweg 30, B-2340 Beerse (BE).		
Published <i>With international search report.</i>			

(54) Title: RISPERIDONE PAMOATE

### (57) Abstract

A compound which is a pamoate acid addition salt of risperidone, compositions comprising the same and processes for preparing said compound and compositions.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## RISPERIDONE PAMOATE

5 EP-0,196,132 discloses the compound 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one, that is known generically as risperidone and is a potent antipsychotic. Unfortunately, the current formulations of risperidone only yield effective plasma levels during a limited time interval. Long-acting injectable risperidone dosage forms would be valuable in  
10 maintenance therapy and would enhance patient compliance.

Currently available long-acting neuroleptics include solutions in oils, e.g. sesame oil, of poorly water-soluble ester derivatives of the neuroleptic compounds. Trials to prolong the activity of some particular phenothiazine neuroleptics by the use of poorly water-soluble salts such as the pamoates proved to be little successful (e.g. Florence et al.,  
15 1976, J. Pharm. Sci., 65(11), 1665-1668). Unexpectedly, the use of the pamoate salt of risperidone in dogs significantly prolonged the release of risperidone, yielding plasma levels of risperidone and its active metabolite that were effective against apomorphine induced emesis during several weeks.

20 Accordingly, the present invention is concerned with the pamoate acid addition salts of risperidone. In particular, the invention is concerned with the compound having the formula



25 The period during which effective plasma levels are obtained depends on the physical characteristics of the risperidone pamoate powder sample, such as particle size and crystal form.

30 Risperidone, its preparation and the pharmacological activity thereof are described in EP-0,196,132. The pamoate salt of risperidone can be prepared by the treatment of

risperidone with pamoic acid or a salt derivative thereof, e.g. the disodium pamoate, in a reaction-inert solvent. In particular, risperidone pamoate can be prepared by adding a solution of risperidone in an appropriate solvent, e.g. ethanol, to a solution of pamoic acid in an appropriate solvent, e.g. N,N-dimethylformamide, and stirring the mixture until precipitation of the risperidone pamoate salt. The reaction product may be isolated from the medium and, if necessary, further purified according to methodologies generally known in the art such as, for example, extraction, crystallization and chromatography. Micronized forms of the subject compounds can be prepared by micronization techniques known in the art, e.g. by milling in appropriate mills and sieving through appropriate sieves.

10 In a particular aspect, the invention relates to the mixed pamoate addition salts of risperidone, e.g. the monosodium pamoate salt of risperidone.

15 The subject compounds are potent antagonists of neurotransmitters and in particular of dopamine. Antagonizing said neurotransmitter suppresses a variety of phenomena induced by the release, in particular the excessive release, of dopamine. Central dopamine receptor blockers are known to have neuroleptic properties, for example, they counteract the positive symptoms of schizophrenia, e.g. hallucinations, delusional thinking, severe excitement and unusual behaviour. Therapeutic indications for using the 20 present compound therefore are mainly in the CNS area, particularly as potent antipsychotic agents and especially as agents useful in treating chronic psychoses. The present compounds also show central serotonin antagonism. Central acting serotonin antagonists appear to improve the negative symptoms of schizophrenia, e.g. anergy, apathy, social withdrawal and depressive mood, and also to reduce the incidence of 25 extrapyramidal side-effects (EPS) during maintenance therapy with classical neuroleptics, i.e. dopamine antagonists. Combined dopamine-serotonin antagonists are especially interesting as they offer relief of both the positive and negative symptoms of schizophrenia with low EPS liability.

30 The subject compounds show the advantage of being long acting dopamine antagonists by the sustained release of risperidone from the poorly water-soluble pamoate salts. This can be evidenced, for example, by measuring the plasma levels after intramuscular or subcutaneous administration to dogs and by the long acting antiemetic effect exerted by the present compounds on dogs challenged with the dopamine agonist apomorphine. Hence, the subject compounds allow administration at relatively large intervals, e.g. at 35 several weeks, the actual time of administration depending on the physical nature of the compound used and the condition of the subject to be treated. Consequently, the present compounds allow for a more efficient therapy : the sustained release facilitates

maintaining a stable plasma concentration at a non-toxic, effective level and the route of administration enhances compliance of the subject to be treated with the prescribed medication.

Unlike most of the currently available long-acting neuroleptics which are usually

5 formulated in an oil for intramuscular administration, the subject compounds show the advantage that they can be formulated in both lipophilic (e.g. an oil) and lipophobic solvents (e.g. aqueous environment) and may be administered in various ways, e.g. intramuscular or subcutaneously.

10 In view of their useful pharmacological properties, the subject compounds may be formulated into various pharmaceutical forms for administration purposes. To prepare the pharmaceutical compositions of this invention, an effective amount of the subject compounds as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms

15 depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration subcutaneously or intramuscularly. For the latter administration routes, the subject compounds preferably are suspended in an aqueous solvent, which may further comprise a wetting agent, such as the polyoxyethylene derivatives of sorbitan esters,

20 e.g. polysorbate 80 (= Tween 80®) and polysorbate 20 (= Tween 20®), lecithin, polyoxyethylene- and polyoxypropylene ethers, sodium deoxycholate, and the like; a suspending agent such as a cellulose derivate, e.g. methylcellulose, sodium

carboxymethylcellulose and hydroxypropyl methylcellulose, polyvinylpyrrolidone,

alginates, chitosan, dextran, gelatin, polyethylene glycols, polyoxyethylene- and

25 polyoxypropylene ethers and the like; an acid, e.g. hydrochloric acid, and the like; a base, e.g. sodium hydroxide, and the like; a buffer comprising a mixture of appropriate amounts of an acid such as phosphoric, succinic, tartaric, lactic, acetic, maleic or citric acid, and a base, in particular sodium hydroxide or disodium hydrogen phosphate; a preservative, e.g. benzoic acid, benzyl alcohol, butylated hydroxyanisole, butylated

30 hydroxytoluene, chlorbutol, a gallate, a hydroxybenzoate, EDTA, phenol, chlorocresol, metacresol, benzethonium chloride, myristyl- $\gamma$ -picolinium chloride, phenylmercuri acetate, thimerosal and the like; a tonicity adjusting agent, e.g. sodium chloride, dextrose, mannitol, sorbitol, lactose; sodium sulfate, and the like

Alternatively, the subject compounds may be formulated in an oil. Appropriate oils for

35 this purpose are fixed oils, for example, peanut oil, sesame oil, cottonseed oil, corn oil, safflower oil, castor oil, ethyoleate, soy bean oil, synthetic glycerol esters of long chain fatty or medium chain acids and mixtures of these and other oils.

Also thickening agents may be added to the composition, e.g. aluminum monostearate, ethylcellulose, triglycerides, hydrogenated castor oil, and the like.

In view of the usefulness of the subject compounds in the treatment of psychotic diseases it is evident that the present invention provides a method of treating warm-blooded animals, in particular humans, suffering from psychotic diseases, said method comprising the administration of a pharmaceutically effective amount of the subject compounds in admixture with a pharmaceutical carrier. In a further aspect, the present invention relates to the use of the subject compounds as a medicine, particularly as an antipsychotic. In general it is contemplated that an effective amount would be from 0.05 mg/kg to 50 mg/kg body weight, more preferably from 0.5 mg/kg to 10 mg/kg body weight.

The following examples are intended to illustrate and not to limit the scope of the present invention.

Example 1

A solution of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one (0.048mol) in ethanol (600ml) was added to a solution of pamoic acid (0.048mol) in *N,N*-dimethylformamide (400ml). The mixture was stirred for 3 hours. The resulting precipitate was filtered off by suction, washed with ethanol and dried, yielding 31g (81%) of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one 4,4'-methylenebis[3-hydroxy-2-naphthalenecarboxylate] (1:1); mp. 269.2°C.

Example 2

*F1 : aqueous suspension*

risperidone monopamoate	25 mg
polysorbate 20	1 mg
benzyl alcohol	10 mg
purified water	q.s. 1 ml

The risperidone monopamoate, polysorbate 20, benzyl alcohol and purified water were intimately mixed and homogenized, thus yielding an aqueous suspension.

In a similar way there were prepared :

-5-

*F2 : aqueous suspension*

	risperidone monopamoate	50 mg
	polysorbate 20	2 mg
	benzyl alcohol	15 mg
5	sodium carboxymethylcellulose	20 mg
	purified water	q.s. 1 ml

*F3 : suspension in oil*

	risperidone monopamoate	50 mg
10	sesame oil	q.s. 1 ml

Example 3

The prolonged action of the risperidone monopamoate salt over the risperidone free base was established by the following procedure

15 The apomorphine test in dogs

The method used is described by P.A.J. Janssen and C.J.E. Niemegeers in *Arzneim.-Forsch.* (Drug Res.), 9, 765-767 (1959). A suspension of the risperidone free base in sesame oil and the risperidone monopamoate compositions F1, F2 and F3 were administered to 3 beagle dogs at a dose between 2 and 2.5 mg/kg. The risperidone free base formula as well as F1 and F3 were administered intramuscularly, whereas F2 was administered subcutaneously. At several time intervals thereafter, the animals were challenged with a standard dose of 0.31 mg/kg (subcutaneous) of apomorphine, which is a potent dopamine agonist and induces emesis. The antiemetic effect of the test compound was used as an indication of its activity.

25

The table hereinbelow summarizes the mean period of activity (days) that was obtained in the 3 test animals.


Mean period of activity (days)	
Risperidone in sesame oil	3
F1	22
F2	18
F3	12

30 From the table it is clear that the administration of risperidone pamoate resulted in a significantly longer period of activity when compared to the administration of the risperidone free base.

Claims

1. A compound which is a pamoate acid addition salt of risperidone.

5 2. A compound according to claim 1 having the formula



10 3. A composition comprising a pharmaceutically acceptable carrier and as active ingredient a pharmaceutically effective amount of a compound as claimed in claim 1.

15 4. A composition according to claim 3 in an injectable dosage form.

5. A composition according to claim 4 which takes the form of an aqueous suspension.

15 6. A composition according to claim 5 further comprising benzyl alcohol, a sorbitan ester and water.

20 7. A composition according to claim 6 further comprising a cellulose derivative.

8. A process for preparing a composition as claimed in claim 3, characterized in that a pharmaceutically effective amount of a compound as claimed in claim 1 is intimately mixed with a pharmaceutically acceptable carrier.

25 9. A compound as claimed in claim 1 for use as a medicine.

10. A process for preparing a compound as claimed in claim 1 characterized by the treatment of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one with pamoic acid in a reaction-inert solvent.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/94/01296A. CLASSIFICATION OF SUBJECT MATTER  
IPC 5 C07D471/04 C07C65/11 A61K31/505 // (C07D471/04, 239:00,  
221:00)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 5 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP, A, 0 196 132 (JANSSEN) 1 October 1986 cited in the application see page 10, line 1 - line 14; claim 1; example 5 -----	1

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*I\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

17 August 1994

Date of mailing of the international search report

26.08.94

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentdaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 cpo nl,  
Fax (+31-70) 340-3016

Authorized officer

Alfaro Faus, I

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International application No.

EP 94/01296

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-0196132	01-10-86	AU-B-	579232	17-11-88
		AU-A-	5529786	02-10-86
		CA-A-	1256867	04-07-89
		CN-B-	1022566	27-10-93
		DE-A-	3686341	17-09-92
		DK-B-	168537	18-04-94
		JP-B-	6013511	23-02-94
		JP-A-	61221186	01-10-86
		SU-A-	1468419	23-03-89
		US-A-	4804663	14-02-89